ADC Therapeutics and Sobi Announce ZYNLONTA(r) (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Source :: Plus Company Updates. September 17, 2022
Publication Year :: 2022
Abstract: LAUSANNE: ADC THERAPEUTICS SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi(r)) today announced the Committee for Medicinal Products for Human [...]

Subjects :: ADC Therapeutics S.A. -- Licensing agreements -- Research agreements
Non-Hodgkin's lymphomas -- Care and treatment
Drug approval
Pharmaceutical industry -- Research agreements -- Licensing agreements
Company licensing agreement
General interest
News, opinion and commentary
European Union. European Commission

Tools